 |
anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein |
|---|---|
| Trade Name | |
| Orphan Indication | Graft Versus Host Disease |
| USA Market Approval | USA |
| USA Designation Date | 2013-09-13 00:00:00 |
| Sponsor | Xenikos BV;Molenveldlaan 152A, 6523RN;NIJMEGEN |
